Levetiracetam Tablet, Film Coated
Product Images NDC 71335-0694

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 71335-0694). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl713350694)

Label for Levetiracetam 500 mg film-coated tablets by Bryant Ranch Prepack. The label indicates a prescription drug with 90 tablets, compares to Keppra 500 mg tablets by Hetero Labs Limited, and includes storage instructions to keep at room temperature 20-25°C (68-77°F) and out of reach of children. The NDC is 71335-0694-1.*

FDA Label Image

Label Image (Lbl713350702)

Levetiracetam 250 mg film-coated tablet packaging label by Bryant Ranch Prepack. The label includes a comparison reference to Keppra 250 mg tablets by Hetero Labs Limited, with a quantity of 60 tablets. It displays storage instructions to keep at room temperature 20-25°C (68-77°F) and a safety warning to keep all drugs out of reach of children. The label also shows an NDC number 71335-0702-1 and a barcode.*

FDA Label Image

Levecamberlogo1

FDA Label Image

Levefig1

A bar chart comparing the percentage of patients across three groups: Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 3000 mg/day. The chart shows patient response percentages with higher values for both Levetiracetam doses compared to placebo.*

FDA Label Image

Levefig2

A bar chart showing the percentage of patients across three groups: Placebo (6.3%), Levetiracetam 1000 mg/day (20.8%), and Levetiracetam 2000 mg/day (35.2%). The chart compares patient response rates by treatment group with patient numbers indicated below each category.*

FDA Label Image

Levefig3

A bar chart comparing the percentage of patients between two groups: placebo (N=104) and Levetiracetam 3000 mg/day (N=180). The placebo group shows 14.4% of patients, while the Levetiracetam group shows 39.4%.*

FDA Label Image

Levefig4

A bar chart comparing the percentage of patients between two groups: Placebo (N=87) and Levetiracetam (N=101). The percentage of patients for the Placebo group is about 19.6%, while for the Levetiracetam group it is about 44.6%. The chart likely represents patient response or outcome data related to Levetiracetam treatment.*

FDA Label Image

Levefig5

A bar graph comparing the percentage of subjects in two groups: Placebo (N=64) at 45.2% and Levetiracetam (N=79) at 72.2%. The y-axis represents percentage of subjects, while the x-axis labels the two groups. The Levetiracetam bar is notably higher than the Placebo bar.*

FDA Label Image

Levefig6

A bar chart comparing the percentage response of two groups: a placebo group (N=64) and a Levetiracetam group (N=79). The Levetiracetam group shows a higher response rate of 72.2% compared to 45.2% in the placebo group.*

FDA Label Image

Levestructure

Chemical structure of Levetiracetam, depicting its molecular arrangement with specific atoms and bonds visible in the diagram.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.